| Year |
Citation |
Score |
| 2024 |
Morales-Prieto N, Bevans R, O'Mahony A, Barron A, Giles Doran C, McCarthy E, Concannon RM, Goulding SR, McCarthy CM, Collins LM, Sullivan AM, O'Keeffe GW. Human α-synuclein overexpression upregulates SKOR1 in a rat model of simulated nigrostriatal ageing. Aging Cell. e14155. PMID 38529808 DOI: 10.1111/acel.14155 |
0.449 |
|
| 2022 |
Mazzocchi M, Goulding SR, Morales-Prieto N, Foley T, Collins LM, Sullivan AM, O'Keeffe GW. Peripheral administration of the Class-IIa HDAC inhibitor MC1568 partially protects against nigrostriatal neurodegeneration in the striatal 6-OHDA rat model of Parkinson's disease. Brain, Behavior, and Immunity. 102: 151-160. PMID 35217173 DOI: 10.1016/j.bbi.2022.02.025 |
0.426 |
|
| 2022 |
McCarthy E, Barron A, Morales-Prieto N, Mazzocchi M, McCarthy CM, Collins LM, Sullivan AM, O'Keeffe GW. Gene Co-expression Analysis of the Human Substantia Nigra Identifies ZNHIT1 as an SNCA Co-expressed Gene that Protects Against α-Synuclein-Induced Impairments in Neurite Growth and Mitochondrial Dysfunction in SH-SY5Y Cells. Molecular Neurobiology. PMID 35175558 DOI: 10.1007/s12035-022-02768-9 |
0.321 |
|
| 2022 |
Goulding SR, Anantha J, Collins LM, Sullivan AM, O'Keeffe GW. Growth differentiation factor 5: a neurotrophic factor with neuroprotective potential in Parkinson's disease. Neural Regeneration Research. 17: 38-44. PMID 34100424 DOI: 10.4103/1673-5374.314290 |
0.442 |
|
| 2021 |
Anantha J, Goulding SR, Tuboly E, O'Mahony AG, Moloney GM, Lomansey G, McCarthy CM, Collins LM, Sullivan AM, O'Keeffe GW. NME1 Protects Against Neurotoxin-, α-Synuclein- and LRRK2-Induced Neurite Degeneration in Cell Models of Parkinson's Disease. Molecular Neurobiology. PMID 34623600 DOI: 10.1007/s12035-021-02569-6 |
0.446 |
|
| 2021 |
Mazzocchi M, Goulding SR, Wyatt SL, Collins LM, Sullivan AM, O'Keeffe GW. LMK235, a small molecule inhibitor of HDAC4/5, protects dopaminergic neurons against neurotoxin- and α-synuclein-induced degeneration in cellular models of Parkinson's disease. Molecular and Cellular Neurosciences. 103642. PMID 34119632 DOI: 10.1016/j.mcn.2021.103642 |
0.48 |
|
| 2021 |
Goulding SR, Lévesque M, Sullivan AM, Collins LM, O'Keeffe GW. Quinacrine and Niclosamide Promote Neurite Growth in Midbrain Dopaminergic Neurons Through the Canonical BMP-Smad Pathway and Protect Against Neurotoxin and α-Synuclein-Induced Neurodegeneration. Molecular Neurobiology. PMID 33713017 DOI: 10.1007/s12035-021-02351-8 |
0.498 |
|
| 2020 |
Goulding SR, Concannon RM, Morales-Prieto N, Villalobos-Manriquez F, Clarke G, Collins LM, Lévesque M, Wyatt SL, Sullivan AM, O'Keeffe GW. Growth differentiation factor 5 exerts neuroprotection in an α-synuclein rat model of Parkinson's disease. Brain : a Journal of Neurology. PMID 33253375 DOI: 10.1093/brain/awaa367 |
0.309 |
|
| 2020 |
Anantha J, Goulding SR, Wyatt SL, Concannon RM, Collins LM, Sullivan AM, O'Keeffe GW. STRAP and NME1 Mediate the Neurite Growth-Promoting Effects of the Neurotrophic Factor GDF5. Iscience. 23: 101457. PMID 32853992 DOI: 10.1016/J.Isci.2020.101457 |
0.541 |
|
| 2020 |
Hegarty SV, Green HF, Niclis J, O'Keeffe GW, Sullivan AM. Editorial: The Role of Stem Cells, Epigenetics and MicroRNAs in Parkinson's Disease. Frontiers in Neuroscience. 14: 515. PMID 32655345 DOI: 10.3389/Fnins.2020.00515 |
0.383 |
|
| 2020 |
Goulding SR, Sullivan AM, O'Keeffe GW, Collins LM. The potential of bone morphogenetic protein 2 as a neurotrophic factor for Parkinson's disease. Neural Regeneration Research. 15: 1432-1436. PMID 31997802 DOI: 10.4103/1673-5374.274327 |
0.549 |
|
| 2020 |
Furlong RM, O'Keeffe GW, O'Neill C, Sullivan AM. Alterations in α-synuclein and PINK1 expression reduce neurite length and induce mitochondrial fission and Golgi fragmentation in midbrain neurons. Neuroscience Letters. 720: 134777. PMID 31978495 DOI: 10.1016/J.Neulet.2020.134777 |
0.421 |
|
| 2019 |
Alshangiti AM, Togher KL, Hegarty SV, Sullivan AM, O'Keeffe GW. The dietary flavonoid isoliquiritigenin is a potent cytotoxin for human neuroblastoma cells. Health Psychology and Behavioral Medicine. 3: NS20180201. PMID 32269833 DOI: 10.1042/Ns20180201 |
0.307 |
|
| 2019 |
Alshangiti AM, Tuboly E, Hegarty SV, McCarthy CM, Sullivan AM, O'Keeffe GW. 4-Hydroxychalcone Induces Cell Death via Oxidative Stress in -Amplified Human Neuroblastoma Cells. Oxidative Medicine and Cellular Longevity. 2019: 1670759. PMID 31885773 DOI: 10.1155/2019/1670759 |
0.337 |
|
| 2019 |
O'Donovan SM, Crowley EK, Brown JR, O'Sullivan O, O'Leary OF, Timmons S, Nolan YM, Clarke DJ, Hyland NP, Joyce SA, Sullivan AM, O'Neill C. Nigral overexpression of α-synuclein in a rat Parkinson's disease model indicates alterations in the enteric nervous system and the gut microbiome. Neurogastroenterology and Motility : the Official Journal of the European Gastrointestinal Motility Society. e13726. PMID 31576631 DOI: 10.1111/Nmo.13726 |
0.434 |
|
| 2019 |
Mazzocchi M, Wyatt SL, Mercatelli D, Morari M, Morales-Prieto N, Collins LM, Sullivan AM, O'Keeffe GW. Gene Co-expression Analysis Identifies Histone Deacetylase 5 and 9 Expression in Midbrain Dopamine Neurons and as Regulators of Neurite Growth via Bone Morphogenetic Protein Signaling. Frontiers in Cell and Developmental Biology. 7: 191. PMID 31572723 DOI: 10.3389/Fcell.2019.00191 |
0.534 |
|
| 2019 |
Furlong RM, Lindsay A, Anderson KE, Hawkins PT, Sullivan AM, O'Neill C. The Parkinson's gene PINK1 activates Akt via PINK1 kinase-dependent regulation of the phospholipid PI(3,4,5)P. Journal of Cell Science. PMID 31540955 DOI: 10.1242/Jcs.233221 |
0.35 |
|
| 2019 |
Goulding SR, Sullivan AM, O'Keeffe GW, Collins LM. Gene co-expression analysis of the human substantia nigra identifies BMP2 as a neurotrophic factor that can promote neurite growth in cells overexpressing wild-type or A53T α-synuclein. Parkinsonism & Related Disorders. PMID 31000327 DOI: 10.1016/J.Parkreldis.2019.04.008 |
0.497 |
|
| 2018 |
Hegarty SV, Sullivan AM, O'Keeffe GW. Inhibition of promotes midbrain neuronal growth through a Smad1/5-dependent mechanism: implications for Parkinson's disease. Neuronal Signaling. 2: NS20170181. PMID 32714583 DOI: 10.1042/NS20170181 |
0.522 |
|
| 2018 |
Crowley EK, Nolan YM, Sullivan AM. Exercise as a therapeutic intervention for motor and non-motor symptoms in Parkinson's disease: Evidence from rodent models. Progress in Neurobiology. 172: 2-22. PMID 30481560 DOI: 10.1016/J.Pneurobio.2018.11.003 |
0.367 |
|
| 2018 |
Paul G, Sullivan AM. Trophic factors for Parkinson's disease: Where are we and where do we go from here? The European Journal of Neuroscience. PMID 30103283 DOI: 10.1111/Ejn.14102 |
0.426 |
|
| 2018 |
O'Keeffe GW, Sullivan AM. Evidence for dopaminergic axonal degeneration as an early pathological process in Parkinson's disease. Parkinsonism & Related Disorders. PMID 29934196 DOI: 10.1016/J.Parkreldis.2018.06.025 |
0.487 |
|
| 2018 |
Crowley EK, Nolan YM, Sullivan AM. Neuroprotective effects of voluntary running on cognitive dysfunction in an α-synuclein rat model of Parkinson's disease. Neurobiology of Aging. 65: 60-68. PMID 29407467 DOI: 10.1016/J.Neurobiolaging.2018.01.011 |
0.413 |
|
| 2017 |
O'Keeffe GW, Hegarty SV, Sullivan AM. Targeting bone morphogenetic protein signalling in midbrain dopaminergic neurons as a therapeutic approach in Parkinson's disease. Neuronal Signaling. 1: NS20170027. PMID 32714578 DOI: 10.1042/NS20170027 |
0.495 |
|
| 2017 |
Hegarty SV, Wyatt SL, Howard L, Stappers E, Huylebroeck D, Sullivan AM, O'Keeffe GW. Zeb2 is a negative regulator of midbrain dopaminergic axon growth and target innervation. Scientific Reports. 7: 8568. PMID 28819210 DOI: 10.1038/S41598-017-08900-3 |
0.417 |
|
| 2017 |
Hegarty SV, Togher KL, O'Leary E, Solger F, Sullivan AM, O'Keeffe GW. Romidepsin induces caspase-dependent cell death in human neuroblastoma cells. Neuroscience Letters. 653: 12-18. PMID 28506690 DOI: 10.1016/J.Neulet.2017.05.025 |
0.323 |
|
| 2017 |
Hegarty SV, Lee DJ, O'Keeffe GW, Sullivan AM. Effects of intracerebral neurotrophic factor application on motor symptoms in Parkinson's disease: A systematic review and meta-analysis. Parkinsonism & Related Disorders. PMID 28215730 DOI: 10.1016/J.Parkreldis.2017.02.011 |
0.379 |
|
| 2017 |
Hegarty SV, Sullivan AM, O'Keeffe GW. Endocytosis contributes to BMP2-induced Smad signalling and neuronal growth. Neuroscience Letters. PMID 28188849 DOI: 10.1016/J.Neulet.2017.02.013 |
0.46 |
|
| 2016 |
Sullivan AM. : an introduction. Neuronal Signaling. 1: NS20160025. PMID 32714575 DOI: 10.1042/NS20160025 |
0.311 |
|
| 2016 |
Hegarty SV, Sullivan AM, O'Keeffe GW. Protocol for evaluation of neurotrophic strategies in Parkinson's disease-related dopaminergic and sympathetic neurons . Journal of Biological Methods. 3: e50. PMID 31453215 DOI: 10.14440/jbm.2016.124 |
0.461 |
|
| 2016 |
Hegarty SV, Sullivan AM, O'Keeffe GW. The Epigenome as a therapeutic target for Parkinson's disease. Neural Regeneration Research. 11: 1735-1738. PMID 28123403 DOI: 10.4103/1673-5374.194803 |
0.443 |
|
| 2016 |
Straley ME, Van Oeffelen W, Theze S, Sullivan AM, O'Mahony SM, Cryan JF, O'Keeffe GW. Distinct alterations in motor & reward seeking behavior are dependent on the gestational age of exposure to LPS-induced maternal immune activation. Brain, Behavior, and Immunity. PMID 27266391 DOI: 10.1016/J.Bbi.2016.06.002 |
0.387 |
|
| 2016 |
Hegarty SV, O'Leary E, Solger F, Stanicka J, Sullivan AM, O'Keeffe GW. A Small Molecule Activator of p300/CBP Histone Acetyltransferase Promotes Survival and Neurite Growth in a Cellular Model of Parkinson's Disease. Neurotoxicity Research. PMID 27256286 DOI: 10.1007/S12640-016-9636-2 |
0.509 |
|
| 2016 |
Sullivan AM, O'Keeffe GW. Neurotrophic factor therapy for Parkinson's disease: past, present and future. Neural Regeneration Research. 11: 205-7. PMID 27073356 DOI: 10.4103/1673-5374.177710 |
0.535 |
|
| 2016 |
Felice VD, Quigley EM, Sullivan AM, O'Keeffe GW, O'Mahony SM. Microbiota-gut-brain signalling in Parkinson's disease: Implications for non-motor symptoms. Parkinsonism & Related Disorders. PMID 27013171 DOI: 10.1016/J.Parkreldis.2016.03.012 |
0.413 |
|
| 2015 |
Collins LM, Dal Bo G, Calcagno M, Monzón-Sandoval J, Sullivan AM, Gutierrez H, Morari M, O'Keeffe GW. Nociceptin/Orphanin FQ Inhibits the Survival and Axon Growth of Midbrain Dopaminergic Neurons Through a p38-MAPK Dependent Mechanism. Molecular Neurobiology. PMID 26687234 DOI: 10.1007/S12035-015-9611-6 |
0.48 |
|
| 2015 |
Hegarty SV, Sullivan AM, O'Keeffe GW. Zeb2: A multifunctional regulator of nervous system development. Progress in Neurobiology. 132: 81-95. PMID 26193487 DOI: 10.1016/J.Pneurobio.2015.07.001 |
0.35 |
|
| 2015 |
Kelly MJ, O'Keeffe GW, Sullivan AM. Viral vector delivery of neurotrophic factors for Parkinson's disease therapy. Expert Reviews in Molecular Medicine. 17: e8. PMID 25997719 DOI: 10.1017/Erm.2015.6 |
0.534 |
|
| 2015 |
Collins LM, Adriaanse LJ, Theratile SD, Hegarty SV, Sullivan AM, O'Keeffe GW. Class-IIa Histone Deacetylase Inhibition Promotes the Growth of Neural Processes and Protects Them Against Neurotoxic Insult. Molecular Neurobiology. 51: 1432-42. PMID 25065734 DOI: 10.1007/S12035-014-8820-8 |
0.469 |
|
| 2015 |
Walsh S, Gavin A, Wyatt S, O'Connor C, Keeshan K, Nolan YM, O'Keeffe GW, Sullivan AM. Knockdown of interleukin-1 receptor 1 is not neuroprotective in the 6-hydroxydopamine striatal lesion rat model of Parkinson's disease. The International Journal of Neuroscience. 125: 70-7. PMID 24628580 DOI: 10.3109/00207454.2014.904304 |
0.336 |
|
| 2014 |
Hegarty SV, O'Keeffe GW, Sullivan AM. Neurotrophic factors: from neurodevelopmental regulators to novel therapies for Parkinson's disease. Neural Regeneration Research. 9: 1708-11. PMID 25422631 DOI: 10.4103/1673-5374.143410 |
0.546 |
|
| 2014 |
Collins LM, Gavin AM, Walsh S, Sullivan AM, Wyatt SL, O'Keeffe GW, Nolan YM, Toulouse A. Expression of endogenous Mkp1 in 6-OHDA rat models of Parkinson's disease. Springerplus. 3: 205. PMID 24826373 DOI: 10.1186/2193-1801-3-205 |
0.458 |
|
| 2014 |
Hegarty SV, Collins LM, Gavin AM, Roche SL, Wyatt SL, Sullivan AM, O'Keeffe GW. Canonical BMP-Smad signalling promotes neurite growth in rat midbrain dopaminergic neurons. Neuromolecular Medicine. 16: 473-89. PMID 24682653 DOI: 10.1007/S12017-014-8299-5 |
0.537 |
|
| 2014 |
Hegarty SV, Sullivan AM, O'Keeffe GW. Roles for the TGFβ superfamily in the development and survival of midbrain dopaminergic neurons. Molecular Neurobiology. 50: 559-73. PMID 24504901 DOI: 10.1007/S12035-014-8639-3 |
0.551 |
|
| 2014 |
Gavin AM, Walsh S, Wyatt S, O'Keeffe GW, Sullivan AM. 6-Hydroxydopamine induces distinct alterations in GDF5 and GDNF mRNA expression in the rat nigrostriatal system in vivo. Neuroscience Letters. 561: 176-81. PMID 24373993 DOI: 10.1016/J.Neulet.2013.12.046 |
0.487 |
|
| 2014 |
Hegarty SV, Spitere K, Sullivan AM, O'Keeffe GW. Ventral midbrain neural stem cells have delayed neurogenic potential in vitro. Neuroscience Letters. 559: 193-8. PMID 24342440 DOI: 10.1016/J.Neulet.2013.12.009 |
0.448 |
|
| 2013 |
Hegarty SV, O'Keeffe GW, Sullivan AM. BMP-Smad 1/5/8 signalling in the development of the nervous system. Progress in Neurobiology. 109: 28-41. PMID 23891815 DOI: 10.1016/J.Pneurobio.2013.07.002 |
0.394 |
|
| 2013 |
Hegarty SV, Sullivan AM, O'Keeffe GW. BMP2 and GDF5 induce neuronal differentiation through a Smad dependant pathway in a model of human midbrain dopaminergic neurons. Molecular and Cellular Neurosciences. 56: 263-71. PMID 23831389 DOI: 10.1016/J.Mcn.2013.06.006 |
0.57 |
|
| 2013 |
Hegarty SV, Sullivan AM, O'Keeffe GW. Midbrain dopaminergic neurons: a review of the molecular circuitry that regulates their development. Developmental Biology. 379: 123-38. PMID 23603197 DOI: 10.1016/J.Ydbio.2013.04.014 |
0.535 |
|
| 2013 |
Collins LM, O'Keeffe GW, Long-Smith CM, Wyatt SL, Sullivan AM, Toulouse A, Nolan YM. Mitogen-activated protein kinase phosphatase (MKP)-1 as a neuroprotective agent: promotion of the morphological development of midbrain dopaminergic neurons. Neuromolecular Medicine. 15: 435-46. PMID 23584919 DOI: 10.1007/S12017-013-8230-5 |
0.585 |
|
| 2013 |
Nolan YM, Sullivan AM, Toulouse A. Parkinson's disease in the nuclear age of neuroinflammation. Trends in Molecular Medicine. 19: 187-96. PMID 23318001 DOI: 10.1016/J.Molmed.2012.12.003 |
0.443 |
|
| 2012 |
Costello DJ, O'Keeffe GW, Hurley FM, Sullivan AM. Transplantation of novel human GDF5-expressing CHO cells is neuroprotective in models of Parkinson's disease Journal of Cellular and Molecular Medicine. 16: 2451-2460. PMID 22436046 DOI: 10.1111/J.1582-4934.2012.01562.X |
0.566 |
|
| 2012 |
Green HF, Treacy E, Keohane AK, Sullivan AM, O'Keeffe GW, Nolan YM. A role for interleukin-1β in determining the lineage fate of embryonic rat hippocampal neural precursor cells. Molecular and Cellular Neurosciences. 49: 311-21. PMID 22270046 DOI: 10.1016/J.Mcn.2012.01.001 |
0.387 |
|
| 2012 |
Toulouse A, Collins GC, Sullivan AM. Neurotrophic effects of growth/differentiation factor 5 in a neuronal cell line. Neurotoxicity Research. 21: 256-65. PMID 21858606 DOI: 10.1007/S12640-011-9266-7 |
0.572 |
|
| 2011 |
Sullivan AM, Toulouse A. Neurotrophic factors for the treatment of Parkinson's disease. Cytokine & Growth Factor Reviews. 22: 157-65. PMID 21689963 DOI: 10.1016/J.Cytogfr.2011.05.001 |
0.519 |
|
| 2010 |
Long-Smith CM, Collins L, Toulouse A, Sullivan AM, Nolan YM. Interleukin-1β contributes to dopaminergic neuronal death induced by lipopolysaccharide-stimulated rat glia in vitro. Journal of Neuroimmunology. 226: 20-6. PMID 20605229 DOI: 10.1016/J.Jneuroim.2010.05.030 |
0.491 |
|
| 2010 |
O'Sullivan DB, Harrison PT, Sullivan AM. Effects of GDF5 overexpression on embryonic rat dopaminergic neurones in vitro and in vivo. Journal of Neural Transmission (Vienna, Austria : 1996). 117: 559-72. PMID 20349094 DOI: 10.1007/S00702-010-0392-9 |
0.548 |
|
| 2010 |
Keohane A, Ryan S, Maloney E, Sullivan AM, Nolan YM. Tumour necrosis factor-alpha impairs neuronal differentiation but not proliferation of hippocampal neural precursor cells: Role of Hes1. Molecular and Cellular Neurosciences. 43: 127-35. PMID 19840854 DOI: 10.1016/J.Mcn.2009.10.003 |
0.501 |
|
| 2009 |
Long-Smith CM, Sullivan AM, Nolan YM. The influence of microglia on the pathogenesis of Parkinson's disease. Progress in Neurobiology. 89: 277-87. PMID 19686799 DOI: 10.1016/J.Pneurobio.2009.08.001 |
0.38 |
|
| 2008 |
Fitzgerald P, Mandel A, Bolton AE, Sullivan AM, Nolan Y. Treatment with phosphotidylglycerol-based nanoparticles prevents motor deficits induced by proteasome inhibition: implications for Parkinson's disease. Behavioural Brain Research. 195: 271-4. PMID 18817814 DOI: 10.1016/J.Bbr.2008.08.041 |
0.442 |
|
| 2008 |
Toulouse A, Sullivan AM. Progress in Parkinson's disease-where do we stand? Progress in Neurobiology. 85: 376-92. PMID 18582530 DOI: 10.1016/J.Pneurobio.2008.05.003 |
0.455 |
|
| 2008 |
Spitere K, Toulouse A, O'Sullivan DB, Sullivan AM. TAT-PAX6 protein transduction in neural progenitor cells: a novel approach for generation of dopaminergic neurones in vitro. Brain Research. 1208: 25-34. PMID 18387597 DOI: 10.1016/J.Brainres.2008.02.065 |
0.585 |
|
| 2008 |
Crotty S, Fitzgerald P, Tuohy E, Harris DM, Fisher A, Mandel A, Bolton AE, Sullivan AM, Nolan Y. Neuroprotective effects of novel phosphatidylglycerol-based phospholipids in the 6-hydroxydopamine model of Parkinson's disease. The European Journal of Neuroscience. 27: 294-300. PMID 18190522 DOI: 10.1111/J.1460-9568.2007.06018.X |
0.449 |
|
| 2007 |
Clayton KB, Sullivan AM. Differential effects of GDF5 on the medial and lateral rat ventral mesencephalon. Neuroscience Letters. 427: 132-7. PMID 17935884 DOI: 10.1016/J.Neulet.2007.09.025 |
0.576 |
|
| 2007 |
Shanley DK, Sullivan AM. Expression of the cell surface markers mAb 2F7 and PSA-NCAM in the embryonic rat brain. Neuroscience Letters. 424: 165-9. PMID 17723277 DOI: 10.1016/J.Neulet.2007.07.054 |
0.425 |
|
| 2007 |
Long C, Sullivan A, Nolan Y. 2.427 The effect of p38 inhibition on the survival of 6-hydroxydopamine-treated rat ventral mesencephalic neurons in vitro Parkinsonism & Related Disorders. 13: S134. DOI: 10.1016/S1353-8020(08)70747-8 |
0.357 |
|
| 2006 |
Shanley DK, Sullivan AM. Alterations in cellular phenotypes differentiating from embryonic rat brain neurosphere cultures by immunoselection of neuronal progenitors. Brain Research. 1067: 85-94. PMID 16269135 DOI: 10.1016/J.Brainres.2005.10.008 |
0.536 |
|
| 2005 |
Sullivan AM, O'Keeffe GW. The role of growth/differentiation factor 5 (GDF5) in the induction and survival of midbrain dopaminergic neurones: relevance to Parkinson's disease treatment. Journal of Anatomy. 207: 219-26. PMID 16185246 DOI: 10.1111/J.1469-7580.2005.00447.X |
0.623 |
|
| 2005 |
Wood TK, McDermott KW, Sullivan AM. Differential effects of growth/differentiation factor 5 and glial cell line-derived neurotrophic factor on dopaminergic neurons and astroglia in cultures of embryonic rat midbrain. Journal of Neuroscience Research. 80: 759-66. PMID 15880784 DOI: 10.1002/Jnr.20507 |
0.737 |
|
| 2005 |
O' Keeffe GW, Sullivan AM. Donor age affects differentiation of rat ventral mesencephalic stem cells. Neuroscience Letters. 375: 101-6. PMID 15670650 DOI: 10.1016/J.Neulet.2004.10.083 |
0.367 |
|
| 2005 |
Sullivan AM, McDermott KW, Butt A, Fraher JP. Symposium on 'Neural stem and progenitor cells: biology and clinical potential', part one Journal of Anatomy. 207: 195-196. DOI: 10.1111/J.1469-7580.2005.00463.X |
0.684 |
|
| 2004 |
O'Keeffe GW, Dockery P, Sullivan AM. Effects of growth/differentiation factor 5 on the survival and morphology of embryonic rat midbrain dopaminergic neurones in vitro. Journal of Neurocytology. 33: 479-88. PMID 15906156 DOI: 10.1007/S11068-004-0511-Y |
0.572 |
|
| 2004 |
O'Keeffe GW, Hanke M, Pohl J, Sullivan AM. Expression of growth differentiation factor-5 in the developing and adult rat brain. Brain Research. Developmental Brain Research. 151: 199-202. PMID 15246706 DOI: 10.1016/J.Devbrainres.2004.04.004 |
0.455 |
|
| 2004 |
Hanke M, Farkas LM, Jakob M, Ries R, Pohl J, Sullivan AM. Heparin-binding epidermal growth factor-like growth factor: a component in chromaffin granules which promotes the survival of nigrostriatal dopaminergic neurones in vitro and in vivo. Neuroscience. 124: 757-66. PMID 15026116 DOI: 10.1016/J.Neuroscience.2003.12.033 |
0.579 |
|
| 2004 |
Hurley FM, Costello DJ, Sullivan AM. Neuroprotective effects of delayed administration of growth/ differentiation factor-5 in the partial lesion model of Parkinson's disease Experimental Neurology. 185: 281-289. PMID 14736509 DOI: 10.1016/J.Expneurol.2003.10.003 |
0.482 |
|
| 2003 |
Wood TK, Sullivan AM, McDermott KW. Viability of dopaminergic neurones is influenced by serum and astroglial cells in vitro. Journal of Neurocytology. 32: 97-103. PMID 14618104 DOI: 10.1023/A:1027384416811 |
0.725 |
|
| 2003 |
Strelau J, Schober A, Sullivan A, Schilling L, Unsicker K. Growth/differentiation factor-15 (GDF-15), a novel member of the TGF-beta superfamily, promotes survival of lesioned mesencephalic dopaminergic neurons in vitro and in vivo and is induced in neurons following cortical lesioning. Journal of Neural Transmission. Supplementum. 197-203. PMID 12946057 DOI: 10.1007/978-3-7091-0643-3_12 |
0.595 |
|
| 2002 |
Krieglstein K, Strelau J, Schober A, Sullivan A, Unsicker K. TGF-beta and the regulation of neuron survival and death. Journal of Physiology, Paris. 96: 25-30. PMID 11755780 DOI: 10.1016/S0928-4257(01)00077-8 |
0.374 |
|
| 2002 |
Sullivan AM, Morton AJ. Endothelins induce Fos expression in neurons and glia in organotypic cultures of rat cerebellum. Journal of Neurochemistry. 67: 1409-1418. PMID 8858922 DOI: 10.1046/J.1471-4159.1996.67041409.X |
0.413 |
|
| 2000 |
Strelau J, Böttner M, Lingor P, Suter-Crazzolara C, Galter D, Jaszai J, Sullivan A, Schober A, Krieglstein K, Unsicker K. GDF-15/MIC-1 a novel member of the TGF-beta superfamily. Journal of Neural Transmission. Supplementum. 273-6. PMID 11205146 DOI: 10.1007/978-3-7091-6301-6_18 |
0.32 |
|
| 2000 |
Strelau J, Sullivan A, Bottner M, Lingor P, Falkenstein E, Suter-Crazzolara C, Galter D, Jaszai J, Krieglstein K, Unsicker K. Growth/differentiation factor-15/macrophage inhibitory cytokine-1 is a novel trophic factor for midbrain dopaminergic neurons in vivo Journal of Neuroscience. 20: 8597-8603. PMID 11102463 DOI: 10.1523/Jneurosci.20-23-08597.2000 |
0.566 |
|
| 1999 |
Sullivan AM, Opacka-Juffry J, Pohl J, Blunt SB. Neuroprotective effects of growth/differentiation factor 5 depend on the site of administration. Brain Research. 818: 176-9. PMID 9914454 DOI: 10.1016/S0006-8993(98)01275-X |
0.367 |
|
| 1998 |
Sullivan AM, Pohl J, Blunt SB. Growth/differentiation factor 5 and glial cell line-derived neurotrophic factor enhance survival and function of dopaminergic grafts in a rat model of Parkinson's disease. The European Journal of Neuroscience. 10: 3681-8. PMID 9875347 DOI: 10.1046/J.1460-9568.1998.00378.X |
0.491 |
|
| 1998 |
Sullivan AM, Opacka-Juffry J, Hötten G, Pohl J, Blunt SB. Growth/differentiation factor 5 protects nigrostriatal dopaminergic neurones in a rat model of Parkinson's disease. Neuroscience Letters. 233: 73-6. PMID 9350835 DOI: 10.1016/S0304-3940(97)00623-X |
0.561 |
|
| 1996 |
Opacka-Juffry J, Ashworth S, Sullivan AM, Banati RB, Blunt SB. Lack of permanent nigrostriatal dopamine deficit following 6-hydroxydopamine injection into the rat striatum. Short communication. Journal of Neural Transmission (Vienna, Austria : 1996). 103: 1429-34. PMID 9029409 DOI: 10.1007/Bf01271256 |
0.38 |
|
| Show low-probability matches. |